A TRIAL OF INDIVIDUAL DOSE INTENSITY AND RELATIVE PERFORMANCE-FACTORS IN TEGAFUR MAINTENANCE CHEMOTHERAPY FOR HEAD AND NECK-CANCER

被引：0
|
作者：
SAWAKI, S
WATANABE, H
SHIN, T
KUBOTA, T
KOMIYAMA, S
UMEZAKI, T
NAHM, I
机构：
[1] SAGA MED SCH,DEPT OTOLARNYGOL HEAD & NECK SURG,SAGA 849,JAPAN
[2] YOKOHAMA CITY UNIV,SCH MED,DEPT OTOLARYNGOL,YOKOHAMA 236,JAPAN
[3] SHOWA UNIV,FUJIGAOKA HOSP,DEPT OTOLARYNGOL,YOKOHAMA 227,JAPAN
[4] KYUSHU UNIV,FAC MED,DEPT OTOLARYNGOL,FUKUOKA 812,JAPAN
来源：
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY | 1993年 / 250卷 / 07期
关键词：
HEAD AND NECK CANCER; CHEMOTHERAPY; INDIVIDUAL DOSE INTENSITY; RELATIVES PERFORMANCE;
D O I：
暂无
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Tegafur (Sunfural-S), as masked compound of a 5-fluorouracil derivative, was administered orally as a maintenance chemotherapeutic agent at a dose of 600 mg/day in 98 cases of head and neck epithelial cancer. The effectiveness of the drug was evaluated by a statistical method involving two formulae: individual dose intensity (IDI) and relative performance (RP). When comparing patients rated above a reference IDI value of 1.0 with those rated below 1.0, it was not possible to predict patient survival or tumor-free rates. In contrast, the value of the RP did show such a correlation. These findings support the effectiveness of Tegafur as a maintenance chemotherapeutic treatment for head and neck cancer patients.
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [1] DOSE INTENSITY OF CHEMOTHERAPY IN RECURRENT AND OR METASTATIC HEAD AND NECK-CANCER
    CHOKSI, AJ
    DIMERY, IW
    GLISSON, BS
    ATKINSON, EN
    MCCARTHY, K
    PAREDES, J
    KRAMER, AM
    HONG, WK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 209 - 209
  • [2] A RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY IN HEAD AND NECK-CANCER
    TAYLOR, SG
    APPLEBAUM, E
    SHOWEL, JL
    NORUSIS, M
    HOLINGER, LD
    HUTCHINSON, JC
    MURTHY, AK
    CALDARELLI, DD
    JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (05) : 672 - 679
  • [3] A CONTROLLED TRIAL OF PALLIATIVE CHEMOTHERAPY IN HEAD AND NECK-CANCER
    MORTON, RP
    STELL, PM
    WILSON, J
    CLINICAL OTOLARYNGOLOGY, 1984, 9 (04): : 249 - 249
  • [4] HEAD AND NECK-CANCER - PROGNOSTIC FACTORS FOR RESPONSE TO CHEMOTHERAPY
    CLAVEL, M
    MANSOUR, ARM
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (03) : 349 - 356
  • [5] RANDOMIZED ADJUVANT CHEMOTHERAPY TRIAL IN ADVANCED HEAD AND NECK-CANCER
    STOLWIJK, C
    VANDENBROEK, P
    WAGENER, DJT
    LEVENDAG, PC
    KAZEM, I
    CLINICAL OTOLARYNGOLOGY, 1983, 8 (04): : 285 - 285
  • [6] FACTORS AFFECTING RESPONSE TO CHEMOTHERAPY FOR ADVANCED HEAD AND NECK-CANCER
    STELL, PM
    MORTON, RP
    WILSON, J
    STONEY, PJ
    CLINICAL OTOLARYNGOLOGY, 1984, 9 (05): : 309 - 309
  • [7] RANDOMIZED NEO-ADJUVANT CHEMOTHERAPY TRIAL FOR ADVANCED HEAD AND NECK-CANCER
    STOLWIJK, C
    WAGENER, DJT
    VANDENBROEK, P
    LEVENDAG, PC
    KAZEM, I
    BRUASET, I
    DEMULDER, PHM
    NETHERLANDS JOURNAL OF MEDICINE, 1985, 28 (09): : 347 - 351
  • [8] INDUCTION CHEMOTHERAPY IN HEAD AND NECK-CANCER - RESULTS OF A PHASE-III TRIAL
    MAZERON, JJ
    MARTIN, M
    BRUN, B
    GRIMARD, L
    LELIEVRE, G
    VERGNES, L
    HADDAD, E
    FEUILHADE, F
    PIEDBOIS, P
    STRUNSKI, W
    PEYNEGRE, R
    PIERQUIN, B
    LEBOURGEOIS, JP
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1992, 14 (02): : 85 - 91
  • [9] METAANALYSIS OF CHEMOTHERAPY IN HEAD AND NECK-CANCER - INDIVIDUAL PATIENT DATA VS LITERATURE DATA
    PIGNON, JP
    BOURHIS, J
    BRITISH JOURNAL OF CANCER, 1995, 72 (04) : 1062 - 1062
  • [10] FACTORS THAT AFFECT RESPONSE TO CHEMOTHERAPY AND SURVIVAL OF PATIENTS WITH ADVANCED HEAD AND NECK-CANCER
    AMER, MH
    ALSARRAF, M
    VAITKEVICIUS, VK
    CANCER, 1979, 43 (06) : 2202 - 2206
12345